Tags

Type your tag names separated by a space and hit enter

Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease.

Abstract

The cannabinoid system is represented by two principal receptor subtypes, termed CB1 and CB2, along with several endogenous ligands. In the central nervous system it is involved in several processes. CB1 receptors are mainly expressed by neurons and their activation is primarily implicated in psychotropic and motor effects of cannabinoids. CB2 receptors are expressed by glial cells and are thought to participate in regulation of neuroimmune reactions. This review aims to highlight several reported properties of cannabinoids that could be used to inhibit the adverse neuroinflammatory processes contributing to Parkinson's disease and possibly other neurodegenerative disorders. These include anti-oxidant properties of phytocannabinoids and synthetic cannabinoids as well as hypothermic and antipyretic effects. However, cannabinoids may also trigger signaling cascades leading to impaired mitochondrial enzyme activity, reduced mitochondrial biogenesis, and increased oxidative stress, all of which could contribute to neurotoxicity. Therefore, further pharmacological studies are needed to allow rational design of new cannabinoid-based drugs lacking detrimental in vivo effects.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Biology, University of British Columbia Okanagan, Kelowna, BC, Canada.

    ,

    Source

    Mini reviews in medicinal chemistry 11:7 2011 Jun pg 582-90

    MeSH

    Animals
    Antioxidants
    Cannabinoids
    Humans
    Inflammation
    Microglia
    Parkinson Disease
    Psychotropic Drugs

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    21699489

    Citation

    Little, J P., et al. "Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated With Parkinson's Disease." Mini Reviews in Medicinal Chemistry, vol. 11, no. 7, 2011, pp. 582-90.
    Little JP, Villanueva EB, Klegeris A. Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease. Mini Rev Med Chem. 2011;11(7):582-90.
    Little, J. P., Villanueva, E. B., & Klegeris, A. (2011). Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease. Mini Reviews in Medicinal Chemistry, 11(7), pp. 582-90.
    Little JP, Villanueva EB, Klegeris A. Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated With Parkinson's Disease. Mini Rev Med Chem. 2011;11(7):582-90. PubMed PMID: 21699489.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease. AU - Little,J P, AU - Villanueva,E B, AU - Klegeris,A, PY - 2011/03/14/received PY - 2011/03/31/accepted PY - 2011/6/25/entrez PY - 2011/6/28/pubmed PY - 2011/10/7/medline SP - 582 EP - 90 JF - Mini reviews in medicinal chemistry JO - Mini Rev Med Chem VL - 11 IS - 7 N2 - The cannabinoid system is represented by two principal receptor subtypes, termed CB1 and CB2, along with several endogenous ligands. In the central nervous system it is involved in several processes. CB1 receptors are mainly expressed by neurons and their activation is primarily implicated in psychotropic and motor effects of cannabinoids. CB2 receptors are expressed by glial cells and are thought to participate in regulation of neuroimmune reactions. This review aims to highlight several reported properties of cannabinoids that could be used to inhibit the adverse neuroinflammatory processes contributing to Parkinson's disease and possibly other neurodegenerative disorders. These include anti-oxidant properties of phytocannabinoids and synthetic cannabinoids as well as hypothermic and antipyretic effects. However, cannabinoids may also trigger signaling cascades leading to impaired mitochondrial enzyme activity, reduced mitochondrial biogenesis, and increased oxidative stress, all of which could contribute to neurotoxicity. Therefore, further pharmacological studies are needed to allow rational design of new cannabinoid-based drugs lacking detrimental in vivo effects. SN - 1875-5607 UR - https://www.unboundmedicine.com/medline/citation/21699489/Therapeutic_potential_of_cannabinoids_in_the_treatment_of_neuroinflammation_associated_with_Parkinson's_disease_ L2 - http://www.eurekaselect.com/88182/article DB - PRIME DP - Unbound Medicine ER -